Nifty
:
18643.80
Sensex
:
63014.19
45.15 (0.24%)
167.81 (0.27%)
Nifty
Sensex
:
:
18643.80
63014.19
45.15 (0.24%)
167.81 (0.27%)

Natco Pharma Ltd.

Pharmaceuticals & Drugs - Global

Rating :
38/99

BSE: 524816 | NSE: NATCOPHARM

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 11,338.55
  • 15.85
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 11,536.45
  • 0.87%
  • 2.56

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 48.84%
  • 2.01%
  • 20.24%
  • FII
  • DII
  • Others
  • 11.91%
  • 14.92%
  • 2.08%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.40
  • -2.30
  • 0.52

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 5.80
  • -22.27
  • -14.67

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.99
  • -24.57
  • -28.28

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 33.20
  • 26.29
  • 36.83

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.98
  • 3.40
  • 3.40

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 23.21
  • 19.36
  • 23.88

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Net Sales
897.90
596.80
50.45%
492.50
560.50
-12.13%
432.10
377.20
14.55%
884.60
410.30
115.60%
Expenses
558.80
615.40
-9.20%
386.60
458.70
-15.72%
336.80
306.70
9.81%
489.30
300.50
62.83%
EBITDA
339.10
-18.60
-
105.90
101.80
4.03%
95.30
70.50
35.18%
395.30
109.80
260.02%
EBIDTM
37.77%
-3.12%
21.50%
18.16%
22.06%
18.69%
44.69%
26.76%
Other Income
29.00
13.80
110.14%
20.80
30.20
-31.13%
20.50
38.00
-46.05%
34.30
17.00
101.76%
Interest
2.70
6.70
-59.70%
3.80
5.00
-24.00%
3.80
4.00
-5.00%
4.20
2.00
110.00%
Depreciation
41.00
38.10
7.61%
41.50
36.00
15.28%
41.70
34.70
20.17%
39.60
33.80
17.16%
PBT
324.40
-49.60
-
81.40
91.00
-10.55%
70.30
69.80
0.72%
385.80
91.00
323.96%
Tax
48.60
0.90
5,300.00%
19.10
10.60
80.19%
13.50
4.70
187.23%
65.40
16.00
308.75%
PAT
275.80
-50.50
-
62.30
80.40
-22.51%
56.80
65.10
-12.75%
320.40
75.00
327.20%
PATM
30.72%
-8.46%
12.65%
14.34%
13.15%
17.26%
36.22%
18.28%
EPS
15.11
-2.77
-
3.41
4.41
-22.68%
3.11
3.57
-12.89%
17.56
4.11
327.25%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
2,707.10
1,944.80
2,052.10
1,915.00
2,094.50
2,184.80
2,020.20
1,141.30
825.28
738.89
660.53
Net Sales Growth
39.20%
-5.23%
7.16%
-8.57%
-4.13%
8.15%
77.01%
38.29%
11.69%
11.86%
 
Cost Of Goods Sold
627.30
528.40
483.70
354.40
332.70
411.10
599.10
341.10
242.37
233.23
242.80
Gross Profit
2,079.80
1,416.40
1,568.40
1,560.60
1,761.80
1,773.70
1,421.10
800.20
582.90
505.67
417.73
GP Margin
76.83%
72.83%
76.43%
81.49%
84.12%
81.18%
70.34%
70.11%
70.63%
68.44%
63.24%
Total Expenditure
1,771.50
1,681.30
1,448.30
1,332.40
1,299.70
1,256.40
1,336.80
868.70
611.90
559.56
510.60
Power & Fuel Cost
-
76.40
61.10
62.40
59.60
56.20
50.50
43.70
43.24
44.77
38.75
% Of Sales
-
3.93%
2.98%
3.26%
2.85%
2.57%
2.50%
3.83%
5.24%
6.06%
5.87%
Employee Cost
-
444.80
414.90
375.00
355.90
325.60
243.20
189.60
136.92
112.77
102.29
% Of Sales
-
22.87%
20.22%
19.58%
16.99%
14.90%
12.04%
16.61%
16.59%
15.26%
15.49%
Manufacturing Exp.
-
344.90
165.70
243.30
276.40
182.60
141.20
105.20
73.04
76.57
65.10
% Of Sales
-
17.73%
8.07%
12.70%
13.20%
8.36%
6.99%
9.22%
8.85%
10.36%
9.86%
General & Admin Exp.
-
161.50
242.90
132.60
126.40
105.50
88.10
73.40
63.66
56.21
39.49
% Of Sales
-
8.30%
11.84%
6.92%
6.03%
4.83%
4.36%
6.43%
7.71%
7.61%
5.98%
Selling & Distn. Exp.
-
43.70
34.40
98.10
90.00
136.90
143.20
91.60
37.36
26.16
14.82
% Of Sales
-
2.25%
1.68%
5.12%
4.30%
6.27%
7.09%
8.03%
4.53%
3.54%
2.24%
Miscellaneous Exp.
-
81.60
45.60
66.60
58.70
38.50
71.50
24.10
15.31
9.85
14.82
% Of Sales
-
4.20%
2.22%
3.48%
2.80%
1.76%
3.54%
2.11%
1.86%
1.33%
1.11%
EBITDA
935.60
263.50
603.80
582.60
794.80
928.40
683.40
272.60
213.38
179.33
149.93
EBITDA Margin
34.56%
13.55%
29.42%
30.42%
37.95%
42.49%
33.83%
23.89%
25.86%
24.27%
22.70%
Other Income
104.60
99.00
106.00
107.40
130.20
40.40
13.90
9.90
14.91
16.71
12.41
Interest
14.50
17.70
13.30
21.50
19.30
15.40
18.50
22.90
31.68
36.62
26.31
Depreciation
163.80
142.60
116.90
99.80
81.00
66.20
54.40
51.00
47.27
30.44
22.12
PBT
861.90
202.20
579.60
568.70
824.70
887.20
624.40
208.60
149.34
128.98
113.90
Tax
146.60
32.20
137.20
110.60
182.30
192.00
139.50
52.80
3.95
30.87
36.44
Tax Rate
17.01%
15.92%
23.67%
19.45%
22.11%
21.64%
22.34%
25.31%
2.94%
23.93%
35.61%
PAT
715.30
170.00
440.90
460.80
644.40
696.20
486.00
157.10
134.62
102.74
71.87
PAT before Minority Interest
715.30
170.00
442.40
458.10
642.40
695.20
484.90
155.80
130.27
98.11
65.88
Minority Interest
0.00
0.00
-1.50
2.70
2.00
1.00
1.10
1.30
4.35
4.63
5.99
PAT Margin
26.42%
8.74%
21.49%
24.06%
30.77%
31.87%
24.06%
13.77%
16.31%
13.90%
10.88%
PAT Growth
320.76%
-61.44%
-4.32%
-28.49%
-7.44%
43.25%
209.36%
16.70%
31.03%
42.95%
 
EPS
39.19
9.32
24.16
25.25
35.31
38.15
26.63
8.61
7.38
5.63
3.94

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
4,263.60
4,121.60
3,773.50
3,489.00
3,072.20
1,649.30
1,295.70
846.05
725.88
533.54
Share Capital
36.50
36.50
36.40
36.50
36.90
34.90
34.80
33.23
33.07
31.37
Total Reserves
4,223.70
4,067.60
3,713.60
3,421.70
3,011.40
1,599.00
1,251.20
812.82
692.80
502.17
Non-Current Liabilities
135.10
142.90
117.80
83.40
47.10
37.70
28.00
119.23
150.67
191.46
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
94.03
92.20
135.62
Unsecured Loans
0.00
0.00
0.90
0.00
0.00
0.00
0.00
2.99
3.28
2.21
Long Term Provisions
95.70
99.60
90.20
71.00
32.40
21.90
12.50
9.50
11.09
8.62
Current Liabilities
710.40
525.60
685.30
728.70
592.00
626.50
493.10
413.74
312.28
344.87
Trade Payables
161.80
146.20
255.40
217.00
269.10
262.70
275.60
125.30
109.79
105.85
Other Current Liabilities
126.70
99.50
95.90
109.80
133.40
127.10
114.20
118.56
102.18
90.21
Short Term Borrowings
404.00
265.80
315.00
386.30
173.20
221.60
98.40
168.54
98.63
147.74
Short Term Provisions
17.90
14.10
19.00
15.60
16.30
15.10
4.90
1.33
1.69
1.07
Total Liabilities
5,109.10
4,791.90
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.41
Net Block
2,311.80
2,023.20
1,584.40
1,227.20
1,018.60
833.00
710.10
709.97
644.74
582.75
Gross Block
3,126.90
2,702.10
2,148.70
1,694.50
1,407.60
1,158.70
983.30
939.98
819.89
726.97
Accumulated Depreciation
815.10
678.90
564.30
467.30
389.00
325.70
273.20
225.82
171.11
140.57
Non Current Assets
2,611.90
2,447.10
2,262.20
1,955.90
1,584.40
1,230.30
984.70
901.08
827.57
749.94
Capital Work in Progress
129.50
223.40
518.00
637.60
480.00
336.30
211.80
128.96
123.78
105.84
Non Current Investment
104.40
151.90
83.60
19.90
8.10
0.10
0.10
1.57
1.57
1.54
Long Term Loans & Adv.
61.50
44.30
72.00
62.80
75.40
60.40
62.10
57.03
54.25
57.20
Other Non Current Assets
4.70
4.30
4.20
8.40
2.30
0.50
0.60
3.54
3.24
2.61
Current Assets
2,497.20
2,344.80
2,325.60
2,347.20
2,130.70
1,087.30
837.00
482.97
368.14
330.48
Current Investments
203.70
151.80
28.70
148.70
68.40
32.10
22.10
0.12
0.32
0.81
Inventories
762.00
798.20
558.00
529.00
438.40
348.90
357.30
220.00
181.12
146.02
Sundry Debtors
620.60
412.90
551.30
506.20
637.50
475.20
261.60
192.43
118.80
129.71
Cash & Bank
206.10
283.50
66.00
279.50
183.70
35.80
45.20
13.36
11.05
10.78
Other Current Assets
704.80
94.70
91.60
107.40
802.70
195.30
150.80
57.06
56.85
43.14
Short Term Loans & Adv.
616.70
603.70
1,030.00
776.40
749.50
169.50
125.40
40.97
52.46
38.85
Net Current Assets
1,786.80
1,819.20
1,640.30
1,618.50
1,538.70
460.80
343.90
69.23
55.85
-14.39
Total Assets
5,109.10
4,791.90
4,587.80
4,303.10
3,715.10
2,317.60
1,821.70
1,384.05
1,195.71
1,080.42

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
46.50
298.80
417.30
668.80
463.60
345.80
112.20
92.67
144.03
61.19
PBT
202.20
579.60
568.70
824.70
887.20
624.40
208.60
134.22
128.98
102.32
Adjustment
123.90
62.10
54.00
14.30
75.60
100.20
90.50
68.14
65.72
48.87
Changes in Working Capital
-231.40
-212.90
-97.60
8.60
-294.60
-253.00
-140.70
-85.96
-16.11
-67.39
Cash after chg. in Working capital
94.70
428.80
525.10
847.60
668.20
471.60
158.40
116.41
178.58
83.80
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-48.20
-130.00
-107.80
-178.80
-204.60
-125.80
-46.20
-23.74
-34.55
-22.61
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-5.30
-103.30
-167.00
-612.20
-1,115.50
-299.40
-175.50
-114.75
-108.92
-107.07
Net Fixed Assets
-204.80
-250.20
-335.80
-436.10
-392.40
-299.40
-303.91
-100.13
-99.70
-102.47
Net Investments
-213.00
-145.90
53.30
-94.80
-54.80
-1.00
37.47
-42.37
-11.33
-2.67
Others
412.50
292.80
115.50
-81.30
-668.30
1.00
90.94
27.75
2.11
-1.93
Cash from Financing Activity
34.80
-185.70
-250.80
-50.90
650.90
-47.70
154.00
29.07
-35.27
26.31
Net Cash Inflow / Outflow
76.00
9.80
-0.50
5.70
-1.00
-1.30
90.70
6.99
-0.15
-19.57
Opening Cash & Equivalents
25.80
19.80
28.30
21.70
23.50
24.20
-164.10
10.22
9.95
34.64
Closing Cash & Equivalent
111.10
25.80
19.80
28.30
21.70
23.50
-74.20
12.44
10.22
9.95

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
233.44
224.88
206.04
189.49
165.22
93.63
73.91
50.91
219.48
170.06
ROA
3.43%
9.43%
10.30%
16.02%
23.05%
23.43%
9.72%
10.10%
8.62%
6.64%
ROE
4.06%
11.27%
12.71%
19.75%
29.70%
33.21%
14.62%
16.57%
15.58%
13.08%
ROCE
4.86%
13.99%
14.82%
23.71%
35.28%
39.21%
18.04%
15.62%
18.02%
16.04%
Fixed Asset Turnover
0.76
0.86
1.07
1.47
1.72
1.93
1.23
0.95
0.96
1.14
Receivable days
85.10
84.44
93.77
91.36
92.22
65.12
70.27
67.76
60.90
61.30
Inventory Days
128.47
118.77
96.38
77.28
65.25
62.41
89.35
87.33
80.17
70.04
Payable days
106.38
151.52
65.96
72.53
81.42
78.30
85.42
73.36
74.09
73.36
Cash Conversion Cycle
107.20
51.68
124.19
96.11
76.05
49.23
74.21
81.73
66.99
57.98
Total Debt/Equity
0.09
0.06
0.08
0.11
0.06
0.14
0.09
0.37
0.33
0.63
Interest Cover
12.42
44.58
27.45
43.73
58.61
34.75
10.11
5.24
4.52
4.89

Annual Reports:

FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014
FY 2013

News Update:


  • Natco Pharma to incorporate subsidiary company in Indonesia
    20th Apr 2023, 12:13 PM

    The balance stake of 49% will be held by PT. Mitra Medis Exim

    Read More
  • Natco Pharma launches additional strengths for generic version of Revlimid in USA
    10th Mar 2023, 09:20 AM

    With this launch the companies made available all the strengths of lenalidomide in the US market

    Read More
  • Natco Pharma launches Pomalidomide Capsules in Canada
    1st Mar 2023, 09:23 AM

    It is the second most common form of blood cancer in Canada with about 8,000 Canadians living with myeloma

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.